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© 2012 The Japan Society of Histochemistry and We aimed to identify whether there is any correlation between chromosomal/genetic changes,
nuclear morphology and the histological grade of urothelial carcinomas of the urinary bladder.
Morphometry and multicolour fluorescence in situ hybridisation (FISH) techniques were
applied to 250 cells in five low-grade cases and 350 cells in seven high-grade cases of
urothelial carcinoma. Compared with low-grade carcinomas, most high-grade cases showed
larger and more variable nuclear size, more frequent polysomy of centromere enumeration
probes (CEPs) 3, 7 and 17, and the loss of the 9p21 locus. The number of CEP signals in
cells was increased as the nuclear area of the cells became larger. Cells with gains in two
or more types of CEP had significantly larger nuclei than cells with normal FISH signal
patterns. In conclusion, the present study indicates that there was a correlation between
nuclear morphology and chromosomal/genetic changes which were related to histological
grading. Thus, we show that differences in the chromosomal/genetic aberrations present in
low- and high-grade tumours can affect not only nuclear morphology but also the
histopathological and clinical behaviour of urothelial carcinomas.
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I. Introduction
Urothelial carcinoma is the most common malignancy
of the urinary bladder [30]. The relative frequency of
urothelial carcinoma in Japan is lower than in Western
countries. However, in recent years, the incidence rate has
increased and the disease accounts for more than 6,000
deaths per year in Japan [17]. According to the 2004 World
Health Organization classification of tumours of the urinary
system, papillary urothelial carcinomas are classified into
four subgroups (low-grade or high-grade, and infiltrating or
non-infiltrating) based on structural and cellular atypia or
stromal invasion [4, 38]. These subtypes of urothelial
carcinomas generally show divergent clinical behaviours.
The low-grade type usually shows frequent recurrence but
rare invasion with good prognosis, whereas the high-grade
type is typified by stromal invasion with poor prognosis or
recurrence with stromal invasion [25]. These different
clinical behaviours necessitate different clinical treatments
for each subgroup of urothelial carcinoma. Transurethral
resection (TUR) is applied in low-grade cases, but in the
high-grade type TUR is followed by Bacillus Calmette-
Guerin (BCG) and/or chemotherapy. Moreover, in cases
presenting muscular invasion (which tend to be high-grade
tumours) total cystectomy is often also required [36].Shuto et al. 26
Various molecular and immunohistochemical analyses
for urothelial carcinomas have been documented [3, 16,
33, 44]. Studies using comparative genomic hybridisation
(CGH) and loss-of-heterozygosity (LOH) analyses reported
both chromosomal gains (1q, 5p, 8q, and 17q) and losses
(2q, 5q, 8p, 9p, 9q, 10q, 11p, 18q and Y) [1, 5, 6, 10, 18,
19, 35, 45]. Furthermore, genetic anomalies or aberrant
expression of genes such as Her2/neu, p53, p16INK4, cyto-
keratins and fibroblast growth factor receptor 3 (FGFR3)
have been found to exist in urothelial carcinoma [2, 3, 6,
26, 42, 43]. Fluorescence in situ hybridisation (FISH) is a
useful technique to detect abnormalities of chromosomes
and genes in various tumours [29, 32]. UroVysion, a
modification of the FISH technique for urothelial carci-
nomas, has been used successfully to assess aberrations in
chromosomes 3, 7, and 17 by centromere enumeration probes
(CEPs), and to detect deletions of p16 at the 9p21 locus
[8]. UroVysion has been revealed as useful cytological
diagnostic tool [13, 24, 40]. Halling et al. suggested that
there was a strong correlation between nuclear size and the
number of abnormal chromosomes present in the nucleus
of urothelial carcinoma cells using UroVysion study [7].
However, combined analysis of FISH signals and nuclear
morphology on a cell by cell basis has not been done.
Biological characteristics of carcinomas (e.g. inva-
siveness or potential for recurrence, prognosis and/or
histopathological findings) are thought to be related to
chromosomal or genetic aberrations, but a clear correlation
has yet to be defined in carcinoma of other organs as well
as urothelial carcinoma [22, 23, 28]. From a clinical
viewpoint, accurate evaluation of cellular atypia is important
for distinguishing low- and high-grade urothelial carcinomas
[4, 36]. Some previous reports indicated chromosomal
and genetic difference between low- and high-grade cases.
However, there is no previous study which clarifies the
relationship between nuclear morphology and chromosomal/
genetic aberrations of urothelial carcinoma in each cell level
[14]. In this study, we analysed chromosomal/genetic
aberrations and nuclear morphology of the same urothelial
carcinoma cells and clarified the correlation between
chromosomal/genetic changes and cell nuclear atypia on a
cell by cell basis.
II. Materials and Methods
Case selection and histological diagnosis
TUR or surgically-resected samples containing papil-
lary urothelial carcinomas from 12 patients (10 male, two
female; mean age at diagnosis was 67.5 years, range 46–79
years) were selected from the files of Saitama Medical
University International Medical Center (Saitama, Japan).
Histologic classification, grading and staging were per-
formed in accordance with the 2004 World Health Organi-
zation classifications and TNM classification of Malignant
Tumours seventh edition. Twelve papillary urothelial carci-
nomas were diagnosed (by histological grading and staging)
as follows: five non-invasive low-grade types; two non-
invasive high-grade types; and five invasive high-grade
types, including four cases with lamina propria invasion
(pT1) and one with muscular invasion (pT2). The four cases
with stage of pT1 were divided two with focal invasion and
two with diffuse invasion. Patient case summaries can be
seen in Table 1. This study was carried on approval by IRB
committee of International Medical Center Saitama Medical
University (No. 08-070).
Cell isolation
For our FISH study, we obtained single cells (with whole
Table 1. Case summary and results of Urovysion analysis
In total, samples were used from 12 patients. Details of patient age and gender, and the grade and invasiveness of their carcinoma are shown. Cells
were analysed from each case sample for a number of FISH staining characteristics, including the expression of chromosome enumeration probes
(CEPs) 3, 7 and 17; loss of one or both 9p21 loci, and the ratio of cells expressing 9p21 and CEP9. Shown are the numbers of cells (out of 50 cells
per sample) showing each type of aberration. Boxes with light and dark grey background indicate aberrant results based on criteria of Vysis. Boxes
with dark grey backgrounds exhibit aberrant results with complete loss of 9p21.
Case # Age (years) Gender Grade pT category (Invasiveness) CEP3,7,17
9p21
9p21/CEP9
Single signal No signal
16 3M
Low pTa (non-invasive)
11 4 0 12
26 0F 1 0 0 0
37 7M 2 8 0 3
46 4M 0 5 0 4




49 19 12 39
77 7M 3 2 0 2
86 4M
pT1 (focally invasive)
34 10 0 7
97 8M 15 19 22 25
10 67 F
pT1 (diffusely invasive)
46 30 8 37
11 46 M 40 2 43 48
12 75 M pT2 (diffusely invasive) 42 1 44 46FISH and Morphometric Analyses of UC 27
nuclei) isolated from formalin-fixed paraffin-embedded
(FFPE) blocks of the tumour tissue. We took 50 µm-thick
sections from FFPE blocks of each sample. After dewaxing
and hydration in PBS (60°C, 24 hr), the thick sections were
minced and incubated with proteinase K (Sigma, St. Louis,
MO, USA), (38 µg/ml in PBS, 37°C, 10 min). After repeated
pipetting to disperse cells, the samples were filtered and
fixed with Carnoy’s fluid (methanol: acetic acid, 3:1). The
isolated single cells in the samples were smeared on slide
glass using by Hanabi Metaphase Spreader (Adstec, Chiba,
Japan). The same procedures for fixation, preparation of
FFPE block and cell isolation were also used to study nuclear
morphology in each case.
Staining for multicolour FISH
For multicolour FISH, we used centromere enumeration
probe (CEP) 9 (GSP, Kanagawa, Japan) together with the
UroVysion (Abbott, Des Moines, IA, USA) containing
VysisTM CEP probes for chromosomes 3, 7, 17 and a unique
probe for the 9p21 locus of p16 gene (LSI p16 (9p21)).
These probes are labelled with the Vysis fluorophores
SpectrumOrange, SpectrumRed, SpectrumGreen, Spectrum-
Aqua and SpectrumGold, respectively. CEP9 was used to
detect cases in which the concurrent gain of chromosome 9
and loss of 9p21 resulted in an apparently unchanged
appearance of 9p21. Multicolour FISH was performed
according to the manufacturer’s instructions and recommen-
dations. Briefly, the slides were incubated in 2× saline
sodium citrate (SCC) at room temperature for 5 min, 0.2 N
HCl for 20 min, then treated with Vysis pre-treatment
solution kit (Abbott, Des Moines, IA, USA) following the
manufacturer’s instructions. Finally, cells were fixed in
buffered formalin for 5 min at room temperature. The slides
were placed in 70%, 85% and 100% ethanol for 1 min
each, and then dried by air. They were denatured in 70%
formamide/2× SCC for 5 min at 72°C. The FISH probe
mixture was denatured for 5 min at 72°C. Denatured slides
were hybridised overnight at 37°C. The slides were
washed in 2× SCC/0.3% NP40 for 2 min at 72°C. After
nuclear counterstaining with 4,6-diamino-2-phenylindole
dihydrochloride (DAPI), the numbers of FISH signals were
counted under a Zeiss microscope (Carl Zeiss Japan, Tokyo,
Japan).
Assessment of FISH signals and nuclear morphology
We analysed 50 tumour cells on each smear slide.
Morphological parameters and FISH signals of the five
probes were quantitatively measured for each cell using
the Isis FISH Imaging system v5.1 (MetaSystems GmbH,
Altlussheim, Germany). As morphological parameters, we
measured nuclear area, maximum nuclear length and nuclear
shape factor (NSF), which was calculated by the formula
(major axis/2)2×3.14/area [21]. The NSF value of a perfectly
round nucleus should be 1.0. To assess gain of chromosomes
and loss of the 9p21 locus, FISH signals from the five probes
were evaluated in the same 50 cells used for measurement
of the nuclear morphological parameters. Normal cells have
two FISH signals per probe. Gain of chromosomes and loss
of 9p21 locus were defined based on criteria defined by
Vysis [39]. Briefly, the cases including more than eight
nuclei with two or more CEPs for chromosomes 3, 7, and
17 were defined as polysomy. Loss of 9p21 was defined as
the cases exhibiting more than 24 cell nuclei with only one
or no 9p21 signal. Ratio of 9p21 and CEP9 was calculated
to detect those cases where gain of chromosome (CEP) 9
masked the concurrent loss of 9p21.
Combining FISH and morphometric analyses in low-grade 
and high-grade groups
The results of combined FISH and morphometric
analyses in 250 cells in the low-grade group and 350 cells
in the high-grade group were compared. The cells in both
groups were divided to subgroups based on median values
of nuclear size (113.6 µm2) and NSF (1.44). Namely, the
cells in low- and high-grade groups were classified into
‘small’ (27.8 to 113.6 µm2) and ‘large’ (113.7 to 375.2
µm2) nuclear subgroups, and into ‘round’ (1 to 1.44) and
‘non-round’ (>1.44) nuclear subgroups. Finally, the mean
number of FISH signals was compared between small versus
large and round versus non-round nuclear subgroups in both
low- and high-grade carcinoma cell samples.
Correlation between nuclear morphology and number of 
FISH signals
The 600 cells analysed as above were taken together
and grouped into six groups according to their FISH signal
characteristics. Normal (‘NM’) cells showed two signals for
all probes. Cells exhibiting gain of CEPs were grouped into
either ‘GoneCEP’ or ‘GmultiCEP’ groups if they contained
a single or multiple CEP gain, respectively. ‘L9p21’ group
cells were those missing the 9p21 locus but without gain of
CEPs, while cells in the ‘GoneCEP & L9p21’ group had
lost the 9p21 locus but with concurrent gain of a single CEP.
Finally, the ‘GmultiCEPs & L9p21’ group contained those
cells with missing 9p21 and concurrent gain of multiple
CEPs. Nuclear morphometric parameters were statistically
compared between NM and the other five groups, and the
correlation between nuclear morphology and the number of
FISH signals was analysed.
Statistical analysis
Statistical analysis was performed using two-sided
Mann-Whitney U-test and Steel-Dwass test. A p value of
less than 0.05 was considered statistically significant.
III. Results
Assessment of FISH signals in low-grade and high-grade 
cases
Representative images of normal and aberrant patterns
of FISH signals are shown in Figure 1. Results of FISH
signal analysis of each case are summarised in Table 1.
Among five non-invasive low-grade urothelial carcinomas,
one showed polysomy and another indicated loss of 9p21.Shuto et al. 28
In seven high-grade urothelial carcinomas, six revealed
polysomy, and five indicated loss of 9p21. All five invasive
high-grade cases showed polysomy. Complete loss of the
9p21 locus (manifested as the absence of any FISH signal
for 9p21) was found in the cases with diffuse invasion. The
aberrant 9p21/CEP9 ratios were consistent with the loss of
9p21.
Assessment of FISH signals and nuclear morphology in 
low-grade and high-grade groups
Table 2 shows the averages and standard deviation of
number of CEPs and 9p21 signals, nuclear area, and nuclear
shape factor based on our assessment of FISH signals and
nuclear morphology of 250 and 350 cells from low- and
high-grade cases, respectively. Figure 2 graphically indi-
cates the results shown in Table 2. Figure 2a shows
distribution of nuclear area in the cells in low- and high-
Fig. 1. Representative results of multicolour FISH analyses of low- and high-grade urothelial carcinomas. a–c) Low-grade case (case no. 3);
d–f) High-grade case (case no. 12); a, d) HE stain (original magnification ×40); b, e) Multicolour FISH stain (original magnification ×63);
c, f) Frequency of cells with each number of FISH signals in that sample. Normal (two FISH signals from all five probes (b, c)) and abnormal
(more than two CEP signals and loss of 9p21 signals (e, f)) patterns can be seen in these Figures.FISH and Morphometric Analyses of UC 29
grade groups. Nuclear area of the cells in the high-grade
group (mean±SD: 136.9±65.1 µm2) was significantly larger
than that in the low-grade group (mean±SD: 108.9±51.0
µm2) (Table 2, p<0.001). The cells in the high-grade group
also had wider variation in nuclear size. Figure 2c reveals
the distribution of NSF in the cells in low- and high-grade
groups. There was no significant difference in the NSF of
cells in low-grade (mean±SD: 1.67±0.74) and high-grade
(mean±SD: 1.55±0.50) groups. The number of CEP signals
was significantly greater in cells from the high-grade group
(mean±SD: 9.8±3.1) than the low-grade group (mean±SD:
6.4±1.4) (Table 2, p<0.001), and the number of 9p21 signals
was significantly lower (high-grade: mean±SD: 1.2±1.2;
low-grade: mean±SD: 1.7±0.8) (Table 2, p<0.001).
Combined analysis of FISH signals and nuclear morphology 
on a cell by cell basis in low-grade and high-grade groups
Figure 2b indicates the correlation between the mean
number of FISH signals and the nuclear area in the cells
from low- and high-grade carcinoma samples (total 250 and
350 cells, respectively). The number of CEP signals per cell
was positively correlated to the nuclear area of the cells,
Table 2. Averages of numbers of FISH signals, nuclear area and nuclear shape factor
Cells from low- and high-grade samples of urothelial carcinoma were analysed for the number of CEPs and 9p21 signals, their average nuclear
area, and their average nuclear shape factor (NSF). Data are mean±SD (median in parentheses). Differences in these parameters between low-
and high-grade samples were assessed for statistical significance using a two-sided Mann-Whitney U-test and Steel-Dwass test. * denotes
p<0.001, which was considered statistically significant.
Number of cells Number of CEP signals Number of 9p21 signals Nuclear area (µm2) NSF
Low grade 250 6.4±1.4 (6)* 1.7±0.8 (2)* 108.9±51.0 (101.2)* 1.67±0.74 (1.48)
High grade 350 9.8±3.1 (10)* 1.2±1.2 (1)* 136.9±65.1 (122.1)* 1.55±0.50 (1.41)
Total 600 8.3±3.0 (7) 1.4±1.1 (2) 125.2±61.2 (113.6) 1.60±0.61 (1.44)
Fig. 2. Nuclear area, nuclear shape factor (NSF) and mean number of FISH signals in 250 low-grade and 350 high-grade carcinoma cells. a) Dis-
tribution of nuclear area in low- and high-grade groups, b) Correlation of nuclear area and number of FISH signals (CEPs 3, 7, 17 and 9p21) per
cell, c) Distribution of NSF in low- and high-grade groups, d) Correlation of NFS and number of FISH signals (CEPs 3, 7, 17 and 9p21) per
cell. For comparison, mean numbers of CEP and 9p21 signals in normal cells are 6 and 2 per cell, respectively.Shuto et al. 30
and this tendency was more prominent in the high-grade
group, as shown in Figure 2b. There was no apparent
correlation between the number of CEP signals and the NSF
(Fig. 2d).
Figures 3a and 3b show comparisons of the numbers
of FISH signals between the ‘small nucleus’ and ‘large
nucleus’ subgroups of the low- and high-grade groups. In
the low-grade group, there were 151 cells with small nuclei
and 99 cells with large nuclei. In the high-grade group, 149
cells had small nuclei and 201 cells had large nuclei,
indicating that high-grade tumours generally have larger
nuclei. In both low- and high-grade groups, the number of
CEP signals in the large nuclear subgroups (mean±SD:
6.8±1.8 (low grade) and 10.5±2.9 (high grade)) was
significantly greater than in the small nuclear subgroups
(mean±SD: 6.1±1.0 (low grade) and 8.7±3.0 (high grade))
(Fig. 3a). The number of 9p21 signals in the small nuclear
subgroup (mean±SD: 1.7±0.7) was significantly less than
that in large nuclear subgroup (mean±SD: 1.9±1.0) in the
low-grade group, but was no different when comparing small
and large nuclear subgroups in the high-grade group
(Fig. 3b). Figures 3c and 3d show comparisons of the
numbers of FISH signals in the round (112 (low grade); 188
(high grade)) and non-round (138 (low grade); 162 (high
grade)) nuclear subgroups. The number of CEP and 9p21
signals were not significantly different between round and
non-round nuclear subgroups, with the exception of CEPs
in the round (mean±SD: 9.4±3.1) and non-round (mean±SD:
10.2±3.0) nuclear subgroups of the high-grade group
(p<0.05, Fig. 3c and 3d).
Correlation between nuclear morphology and number of 
FISH signals based on a cell by cell analysis
A total of 600 cells were divided into six groups
according to the number of identifiable FISH signals, and
these groups were analysed to determine whether there was
any correlation between nuclear morphology and the number
of FISH signals. Cells exhibiting gains in two or more kinds
of CEPs (GmultiCEPs group, and GmultiCEPs & L9p21
group) had significantly larger nuclei than cells with normal
FISH signal patterns (NM group) (p<0.05, Fig. 4). However,
compared with NM group, cells having gain of only one
Fig. 3. a, b) Comparison (between small and large nuclear subgroups (N_SubG) in the low- and high-grade groups) of a) the distribution of the
total number of CEP signals (CEPs 3, 7, 17) per cell, and b) the number of 9p21 signals per cell. c, d) Comparison (between round and non-
round nuclear subgroups (N_SubG) in low- and high-grade groups) of c) the distribution of the total number of CEP signals (CEPs 3, 7, 17) per
cell, and d) the number of 9p21 signals per cell. Value above columns is the mean±SD for each condition.FISH and Morphometric Analyses of UC 31
kind of CEP or a loss of 9p21 showed no significant
difference in nuclear area. There was no correlation between
NFS and gain of chromosome/loss of 9p21.
IV. Discussion
Urothelial carcinomas show diverse histological grad-
ing and stages associated with a variety of pathological and
clinical behaviors [15]. Typically, low-grade cases with good
prognosis rarely show invasion despite frequent recurrence,
whereas high-grade cases with poor prognosis indicate
stromal invasion or recurrence with invasion. These diver-
gent behaviours may be explained by genetic alterations
[19]. Previous studies have reported that urothelial carcino-
mas have diverse chromosomal and genetic abnormalities
related with histopathological finding, grading and staging
[1, 6, 10, 19, 24, 31, 43]. For instance, FGFR3 and p53
clearly  play  an  important role in carcinogenesis of low-
grade papillary urothelial carcinomas and high-grade
urothelial carcinomas, respectively [35, 41, 43]. Thus, some
pathologically and clinically interesting correlations between
histopathological grading and chromosomal/genetic aberra-
tion have been suggested. However, there is no study which
clarifies the relationship between nuclear morphology and
chromosomal/genetic aberrations of urothelial carcinoma on
a cell by cell basis.
The UroVysion multicolour FISH technique, which
detects the most common chromosomal and genetic aberra-
tions in urothelial carcinoma cells, has been a popular clinical
application for detection of carcinoma cells in urine [4, 8,
40]. The present study indicates a strong correlation between
histological grading and chromosomal/genetic aberration.
Most high-grade cases showed both polysomy and loss of
9p21 locus, whereas most low-grade cases did not. The
result is compatible with a previous study describing a
positive correlation between FISH results and both tumour
invasiveness and histological grade [40]. Moreover, two of
three diffusely invasive high-grade cases indicated complete
loss of the 9p21 locus. Since chromosomes 3, 7, and 17
include tumour growth factors such as RAS family, EGFR
and c-erbB-2, and the 9p21 locus encodes p16 tumour
suppressor factor, there is a possibility that the cell
proliferation activity of urothelial carcinomas might affect
their histological grading and invasive potential [26]. The
findings of our study suggest that cytogenetic analysis by
multicolour FISH can be a useful ancillary tool for diagnosis
and surveillance of histological and clinical behaviours in
urothelial carcinomas.
Generally, normal cells show round or non-round nuclei
with smooth nuclear contours, whereas carcinoma cells have
morphological abnormalities of the nucleus (i.e. nuclear
atypia) represented by large nuclei and irregular nuclear
contours [20]. This nuclear atypia is a characteristic feature
of carcinoma cells and seems to be related to carcinogenesis
[20, 22, 23, 37]. The general role of nuclear feature formation
is not clear for either normal or carcinoma cells. Past reports
have studied the nuclear morphogenesis of normal cells
based mainly on nuclear envelope organisation and cyto-
skeletal features [11, 28, 34]. On the other hand, it is sug-
gested that there is some correlation between nuclear atypia
and chromosomal/genetic aberrations. However, few reports
have studied the nuclear morphogenesis of carcinoma cells
in relation to chromosomal or genomic aberrations on a cell
by cell basis [9, 23]. The present study indicates several
correlations in each cell level between chromosomal/genetic
aberration and nuclear morphology. For instance, nuclear
size in the high-grade group was significantly larger and
more variable than that in low-grade group. Furthermore,
the number of CEP signals was increased as the nuclear
area of the cells grew larger (a trend that was more prominent
in high-grade than low-grade samples), and the number of
CEP signals was apparently related to nuclear size in both
low- and high-grade cases. Namely a larger nucleus is linked
to an increase in CEP signals. Finally, the number of 9p21
signals was also correlated to nuclear size, being lower in
those cells with small nuclei than in those with larger nuclei,
although only in low-grade cases. Interestingly, cells in the
high-grade group not only had large nuclei but also many
smaller nuclei and these small nuclei had prominent
aberrations in CEP signals. Conversely, larger nuclei of cells
in the low-grade group revealed less CEP aberrations, and
thus the variation of nuclear size in the low-grade group
may be due to cell cycle processes rather than chromosomal
aberration [21]. There were no significant differences in
Fig. 4. Correlation between nuclear area and gain of chromosome or
loss of 9p21. A total of 600 cells was grouped by the number of
identifiable FISH signals. ‘NM’ denotes normal cells with two sig-
nals for each probe; ‘GoneCEP’ denotes cells with gain of one kind
of chromosome; ‘GmultiCEPs’ group indicates cells with gains of
two or more CEPs; ‘L9p21’ contains those cells exhibiting loss of
9p21 but without any gain of CEPs; ‘GoneCEP & L9p21’ denotes
cells with both gain of one kind of CEP and loss of 9p21; and the
‘GmultiCEPs & L9p21’ group of cells exhibit a gain of two or more
kinds of CEPs together with the loss of 9p21.Shuto et al. 32
NSF between low- and high-grade groups, and (with one
exception) no correlation between the number of CEP or
9p21 signals and nuclear roundness. Thus, nuclear shape
and chromosomal/genetic aberration appear not to be linked
in the same way as nuclear area and chromosomal/genetic
aberration. To analyse in more detail the correlation between
nuclear shape and chromosomal/genetic aberration, further
study using different NSFs may be required [21].
Interestingly, analysis based on a total of 600 tumour
cells showed that those cells exhibiting gains of two or
more kinds of CEPs had significantly larger nuclei than cells
with normal FISH signal pattern. In contrast, cells gaining
only one kind of CEP or losing 9p21 showed no significant
difference in nuclear area. These results suggest that large
changes in nuclear size depend on gross alterations at the
chromosomal, rather than the genomic, level. This conclu-
sion is supported by the observation that papillary thyroid
carcinoma cells with only point mutation or transformation
without any evident increase of chromosomes show negli-
gible changes in nuclear morphology [12, 23, 27].
In conclusion, we show here that there is a correlation
between chromosomal/genetic changes and nuclear mor-
phology in each cell level. Differences in these chromo-
somal/genetic aberrations between low- and high-grade
cases may affect the nuclear morphology as well as
biological behaviour (invasivity or recurrence potential) of
carcinomas and their prognosis.
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